When Bapi failed, Prana came out with a news release that proactively differentiated the MOA of PBT2 versus Bapi and Sola so that there was no reaction against Prana on the bad news of the Bapi failure, bringing into question the Amyloid-beta theory in general.
As I recall it was effective at drawing attention to ourselves. I would sure love to see them right about now come up with a very positive counter-release about PBT2 and how we are about to bring about a paradigm shift in the cause of the disease and how to treat it.
A perfect opportunity is hereby presented :-)
nejm solanezumab, page-6
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $21.28M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $8.4K | 2.1M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 67 | 79035427 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 115463117 | 7 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| ATH (ASX) Chart |